{"entity":{"id":"idea-upgrade-rituximab-igm-flare-prevention-comparison","kind":"idea","name":"Plasma exchange before rituximab compared with holding rituximab back, for a high IgM in Waldenström macroglobulinaemia","aka":[],"tldr":"Rituximab can push the abnormal IgM protein up for a few weeks before bringing it down, which can thicken the blood when the level is already high. Hospitals prevent this differently: plasma exchange first, leaving rituximab out of the first cycles, or watching closely. No study has compared them, and the two guidelines that recommend acting grade their evidence as low.","summary":"What the guidelines say. The British Society for Haematology guideline (2022) says the introduction of rituximab should be deferred, or prophylactic plasmapheresis performed, when IgM or M-protein is above 40 g/L, and grades this C1. The American Society for Apheresis (2026) gives plasma exchange before rituximab its category I with grade 1C, and counts the evidence as 3 case series and 3 case reports, with no randomised or controlled trial; it also offers holding rituximab for 1 to 3 cycles until IgM is below 4 g/dL as the alternative.\n\nThe doubt. In his 2018 review, Gertz writes that it is unproven that pre-emptive plasma exchange in people without symptoms and an IgM above 5000 prevents complications when compared with close monitoring after rituximab and treatment if symptoms develop, and adds that many would not agree and do exchange first.\n\nHow often the flare happens. In an Eastern Cooperative Oncology Group study of rituximab given alone, IgM rose in 29 of 54 patients (54%), and no factor predicting the rise could be identified. The apheresis guideline puts the figure at 30% to 70% within 4 weeks.\n\nWhat each choice costs. Plasma exchange usually needs a central line and an apheresis session. Holding rituximab changes the first cycles of treatment. Watching closely costs blood tests and depends on the person reporting symptoms early. Which route leads to fewer episodes of hyperviscosity has not been measured in any source read.","asOf":"2026-11-16","links":[{"label":"Pratt et al., Guidelines on the diagnosis and management of Waldenström macroglobulinaemia: a British Society for Haematology guideline (Br J Haematol 2022)","url":"https://doi.org/10.1111/bjh.18036"},{"label":"ASFA Guidelines on the Use of Therapeutic Apheresis in Clinical Practice, the Tenth Special Issue: fact sheet on hyperviscosity in hypergammaglobulinemia (J Clin Apher 2026)","url":"https://doi.org/10.1002/jca.70141"},{"label":"Gertz, Acute hyperviscosity: syndromes and management (Blood 2018)","url":"https://doi.org/10.1182/blood-2018-06-846816"},{"label":"Ghobrial et al., Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study (Cancer 2004)","url":"https://doi.org/10.1002/cncr.20658"}],"tags":["protocol-upgrade","upgrade:untested","evidence:insufficient"],"related":[],"cancers":["waldenstrom"],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":["rituximab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-rare-cancers","b-real-world-evidence"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"In people with Waldenström macroglobulinaemia and an IgM above 40 g/L starting a rituximab-containing regimen, leaving rituximab out of the first one to three cycles leads to no more episodes of symptomatic hyperviscosity in the first three months than plasma exchange before the first dose, with fewer central lines and apheresis sessions.","rationale":"The condition is uncommon, so a large randomised trial is unlikely, yet every centre treating it makes this choice. The guidelines grade their advice C1 and 1C and a leading review calls the benefit of pre-emptive exchange unproven, so centres differ, and a patient's route depends on where they are treated.","test":"A prospective registry across Waldenström centres recording, for every patient with IgM above 40 g/L starting rituximab, which of the three approaches was used, the IgM and viscosity at two, four and eight weeks, and any symptomatic hyperviscosity or unplanned plasma exchange within three months; then, if the registry shows genuine uncertainty, a pragmatic randomised comparison of deferred rituximab against exchange first.","maturity":"speculative","actor":"research","cost":"small","horizonYears":4},"route":"/ideas/idea-upgrade-rituximab-igm-flare-prevention-comparison/","neighbours":{"cancer":[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"section":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"drug":[{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"protocol":[{"id":"hyperviscosity-syndrome-plasma-exchange","kind":"protocol","name":"Hyperviscosity syndrome in Waldenström macroglobulinaemia and myeloma: recognition and plasma exchange","route":"/protocols/hyperviscosity-syndrome-plasma-exchange/"}]}}